Abstract
New classes of lipids such as lipoxins, resolvins, protectins and maresin are found to promote the resolution of inflammation. The resolving actions of these endogenous lipids are mediated by membrane receptors such as lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2) and cysteinyl leukotriene receptor 1 (CysLT1). Further, there exists G protein-coupled receptor 32 (GPR32), chemokine receptor-like (CMLKLR), LTB4 receptor 1 (BLT1) and unidentified high-affinity surface binding receptors in human polymorphonuclear leukocytes (PMN). In particular, RX-10001 (resolvin E1) and RX-10004 (synthetic analog of resolvin, phase II) are being studied clinically in many inflammatory diseases including dry eye, retinal disease, asthma, inflammatory bowel diseases, rheumatic arthritis and cardiovascular diseases by Resolvyx Pharmaceuticals. These novel lipid classes of inflammation resolving mediators might offers new opportunities for candidates of drugs modulating chronic inflammatory diseases. Here, the progress of resolvins as new drug candidates is introduced and research on the resolution phase of inflammation is emphasized.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Antoni, C. and Braun, J., Side effects of anti-TNF therapy: current knowledge. Clin. Exp. Rheumatol., 20, S152–S157 (2002).
Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., Blumberg, R. S., and Serhan, C. N., Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. U. S. A., 102, 7671–7676 (2005).
Bannenberg, G. and Serhan, C. N., Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim. Biophys. Acta, 1801, 1260–1273 (2010).
Bazan, N. G., Cellular and molecular events mediated by docosahexaenoic acid-derived neuroprotectin D1 signaling in photoreceptor cell survival and brain protection. Prostaglandins. Leukot. Essent. Fatty Acids, 81, 205–211 (2009).
Bottone, F. G. Jr. and Barry, W. T., Postmarketing surveillance of serious adverse events associated with the use of rofecoxib from 1999-2002. Curr. Med. Res. Opin., 25, 1535–1550 (2009).
Chan, M. M. and Moore, A. R., Resolution of inflammation in murine autoimmune arthritis is disrupted by cyclooxygenase-2 inhibition and restored by prostaglandin E2-mediated lipoxin A4 production. J. Immunol., 184, 6418–6426 (2010).
Gayton, J. L., Etiology, prevalence, and treatment of dry eye disease. Clin. Ophthalmol., 3, 405–412 (2009).
Haworth, O., Cernadas, M., Yang, R., Serhan, C. N., and Levy, B. D., Resolvin E1 regulates interleukin 23, interferongamma and lipoxin A4 to promote the resolution of allergic airway inflammation. Nat. Immunol., 9, 873–879 (2008).
Lawrence, T., Willoughby, D. A., and Gilroy, D. W., Antiinflammatory lipid mediators and insights into the resolution of inflammation. Nat. Rev. Immunol., 2, 787–795 (2002).
Lawrence, T., Inflammation and cancer: a failure of resolution? Trends Pharmacol. Sci., 28, 162–165 (2007).
Levy, B. D., Resolvins and protectins: natural pharmacophores for resolution biology. Prostaglandins Leukot. Essent. Fatty Acids, 82, 327–332 (2010).
Li, N., He, J., Schwartz, C. E., Gjorstrup, P., and Bazan, H. E., Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther, 26, 431–439 (2010).
Nathan, C. and Ding, A., Nonresolving inflammation. Cell, 140, 871–882 (2010).
Navarro-Xavier, R. A., Newson, J., Silveira, V. L., Farrow, S. N., Gilroy, D. W., and Bystrom, J., A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol., 184, 1516–1525 (2010).
Ogawa, S., Urabe, D., Yokokura, Y., Arai, H., Arita, M., and Inoue, M., Total synthesis and bioactivity of resolvin E2. Org. Lett., 11, 3602–3605 (2009).
Rajakariar, R., Yaqoob, M. M., and Gilroy, D. W., COX-2 in inflammation and resolution. Mol. Interv., 6, 199–207 (2006).
Serhan, C. N. and Petasis, N. A., Resolvins and protectins in inflammation resolution. Chem. Rev., 111, 5922–5943 (2011).
Smith, J. A., Albeitz, J., Begley, C., Caffery, B., Nichols, K., Schaumberg, D., and Schein, O., The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international dry eye workShop (2007). Ocul. Surf., 5, 93–107 (2007).
Spite, M., Norling, L. V., Summers, L., Yang, R., Cooper, D., Petasis, N. A., Flower, R. J., Perretti, M., and Serhan, C. N., Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature, 461, 1287–1291 (2009).
Xu, Z. Z., Zhang, L., Liu, T., Park, J. Y., Berta, T., Yang, R., Serhan, C. N., and Ji, R. R., Resolvins RvE1 and RvD1 attenuate inflammatory pain via central and peripheral actions. Nat. Med., 16, 592–597 (2010).
Author information
Authors and Affiliations
Corresponding author
Additional information
Chang Hoon Lee
1984–1988, Seoul National University, Manufacturing Pharmacy, BA
1988–1990, Seoul National University, Biochemical Pharmacy, MS
1990–1995, Seoul National University, Biochemical Pharmacy, PhD
Main Research Areas
New target identification and validation in cancer and inflammation
Isolation and identification of new compounds from soil microorganisms
Resolution of inflammation and cancer
Rights and permissions
About this article
Cite this article
Lee, C.H. Resolvins as new fascinating drug candidates for inflammatory diseases. Arch. Pharm. Res. 35, 3–7 (2012). https://doi.org/10.1007/s12272-012-0121-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-012-0121-z